東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Patient Experience on Therapy for He...

Nickerson, Jillian Elizabeth.

FindBook

Google Book

Amazon

博客來

Patient Experience on Therapy for Hepatitis C Virus, The Impact of Successful Treatment on Liver Stiffness, and The Meaning of Sustained Virologic Response.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Patient Experience on Therapy for Hepatitis C Virus, The Impact of Successful Treatment on Liver Stiffness, and The Meaning of Sustained Virologic Response./
作者:	Nickerson, Jillian Elizabeth.
面頁冊數:	85 p.
附註:	Source: Masters Abstracts International, Volume: 54-04.
Contained By:	Masters Abstracts International54-04(E).
標題:	Medicine. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1587746
ISBN:	9781321719789

Patient Experience on Therapy for Hepatitis C Virus, The Impact of Successful Treatment on Liver Stiffness, and The Meaning of Sustained Virologic Response.
Nickerson, Jillian Elizabeth.

Patient Experience on Therapy for Hepatitis C Virus, The Impact of Successful Treatment on Liver Stiffness, and The Meaning of Sustained Virologic Response. - 85 p.

Source: Masters Abstracts International, Volume: 54-04.

Thesis (M.S.)--Icahn School of Medicine at Mount Sinai, 2015.

This item must not be sold to any third party vendors.

Chronic infection with the hepatitis C virus (HCV) affects nearly 2% of adults in the United States and is the leading indication for liver transplant due to progression to fibrosis and cirrhosis. Two new therapies, sofosbuvir and simeprevir, were approved by the FDA in late 2013. They became widely used in combination without interferon based on a small (n=168) randomized control trial that used a surrogate end point of sustained virologic response 12 weeks after the end of treatment (SVR12). In recent years, transient elastography (FibroScanRTM), an ultrasound technology that measures liver stiffness to estimate fibrosis and cirrhosis noninvasively, has become widely adopted after approval by the FDA in 2013 and recognition for payment by Medicare in 2015. There are few studies on the affect of treatment on side effects and health related quality of life on the new regimens. Little is known about the effect of therapy on existing liver fibrosis or cirrhosis and the natural history of patients after they achieve SVR.

ISBN: 9781321719789Subjects--Topical Terms:

641104
Medicine.

Patient Experience on Therapy for Hepatitis C Virus, The Impact of Successful Treatment on Liver Stiffness, and The Meaning of Sustained Virologic Response.
LDR:03366nmm a2200337 4500 001 2066425
005 20151106144857.5
008 170521s2015 ||||||||||||||||| ||eng d
020 $a 9781321719789
035 $a (MiAaPQ)AAI1587746
035 $a AAI1587746
040 $a MiAaPQ $c MiAaPQ
100 1 $a Nickerson, Jillian Elizabeth. $3 3181217
245 1 0 $a Patient Experience on Therapy for Hepatitis C Virus, The Impact of Successful Treatment on Liver Stiffness, and The Meaning of Sustained Virologic Response.
300 $a 85 p.
500 $a Source: Masters Abstracts International, Volume: 54-04.
500 $a Adviser: Andrea Branch.
502 $a Thesis (M.S.)--Icahn School of Medicine at Mount Sinai, 2015.
506 $a This item must not be sold to any third party vendors.
520 $a Chronic infection with the hepatitis C virus (HCV) affects nearly 2% of adults in the United States and is the leading indication for liver transplant due to progression to fibrosis and cirrhosis. Two new therapies, sofosbuvir and simeprevir, were approved by the FDA in late 2013. They became widely used in combination without interferon based on a small (n=168) randomized control trial that used a surrogate end point of sustained virologic response 12 weeks after the end of treatment (SVR12). In recent years, transient elastography (FibroScanRTM), an ultrasound technology that measures liver stiffness to estimate fibrosis and cirrhosis noninvasively, has become widely adopted after approval by the FDA in 2013 and recognition for payment by Medicare in 2015. There are few studies on the affect of treatment on side effects and health related quality of life on the new regimens. Little is known about the effect of therapy on existing liver fibrosis or cirrhosis and the natural history of patients after they achieve SVR.
520 $a After a review of the relevant literature, we conducted a prospective cohort study of side effects and health related quality of life in patients treated with regimens including sofosbuvir and simeprevir. We also conducted a retrospective study of the change in liver stiffness during treatment, comparing patients who achieved SVR with those who did not. We then wrote a review to establish a foundation for how patients should be followed after achieving SVR.
520 $a We found that patients treated with combination simeprevir/sofosbuvir without ribavirin or interferon had fewer side effects and better health related quality of life than those treated with the regimens including interferon and/or ribavirin. Patients who achieved SVR had more substantial regression of fibrosis as estimated by FibroScanRTM than those who did not achieve SVR.
520 $a Thus, we found that combination sofosbuvir/simeprevir free of interferon and/or ribavirin is more tolerable to patients and result in an improved quality of life relative to baseline. Patients who achieve SVR may experience regression of liver fibrosis and even cirrhosis. Further research is needed to determine the long-term outcomes and optimal follow-up regimens for patients undergoing new treatments for HCV.
590 $a School code: 1734.
650 4 $a Medicine. $3 641104
650 4 $a Medical imaging. $3 3172799
650 4 $a Health care management. $3 2122906
690 $a 0564
690 $a 0574
690 $a 0769
710 2 $a Icahn School of Medicine at Mount Sinai. $b Clinical Research. $3 3181218
773 0 $t Masters Abstracts International $g 54-04(E).
790 $a 1734
791 $a M.S.
792 $a 2015
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1587746